Human RCTPubMed ID: 38726519·2024

TRIUMPH 2: Retatrutide in Type 2 Diabetes and Obesity

Rosenstock J, Cariou B, Seetharaman S, et al.

Diabetes Care, 2024 · n = 1109

Key finding

Retatrutide 15mg reduced HbA1c by 2.5% (95% CI 2.3-2.7%) and body weight by 24.1% vs placebo, with 89% achieving HbA1c <7%.

Summary

Phase 3 trial evaluating retatrutide efficacy and safety in patients with type 2 diabetes and obesity over 68 weeks with dose escalation protocol.

Read the study

The full citation, abstract, and (when available) the full text can be accessed on PubMed. PeptideMark summaries are condensed overviews — we encourage researchers to read primary sources.

View on PubMed

Related compound

RetatrutideL4

A triple-acting GIP/GLP-1/glucagon receptor agonist in Phase 3 trials showing potentially the highest weight loss of any drug in development.

More research on Retatrutide

TRIUMPH-NAS: Retatrutide for Non-Alcoholic Steatohepatitis

Journal of Hepatology · 2025 · Human RCT

TRIUMPH-OA: Retatrutide for Obesity-Related Osteoarthritis

Osteoarthritis and Cartilage · 2025 · Human RCT

Genetic Polymorphisms Predict Retatrutide Response: GWAS Analysis

Cell Metabolism · 2025 · Human RCT

Comparative Efficacy: Retatrutide vs Tirzepatide in Randomized Head-to-Head Trial

New England Journal of Medicine · 2025 · Human RCT

TRIUMPH 1: Retatrutide versus Placebo in Obesity (Phase 3)

Lancet Diabetes & Endocrinology · 2024 · Human RCT